Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214

total

1,338.943

impact factor

6.257

average impact factor

Group Leaders: Mª Jesús Cruz Carmona and Jaume Ferrer Sancho

team

zoom

download

Specifically, within the research in asthma the group is leading the asthma area of CibeRes. In the area of environmental diseases there are various active projects such as the study of interaction between air pollution and asthma. Regarding lung transplant, we are developing several projects linked to our lung transplant biobank. We are going to study the microbiome of lung transplant patients and the role of cell free DNA. In sleep apnea and ventilation, projects include several multicenter studies to find out the impact of sleep apnea on the pediatric population. Regarding COPD, the group will coordinate a multicenter project to know the effectiveness of palliative cures in the final phases of the disease, and a project for the study of pathogenesis of COPD using molecular and computational biology techniques. The group is part of the Catalonian Referral Unit for Cystic Fibrosis, which maintains the Spanish registry of bronchiectasis and patients with a1-antitrypsin deficit.

105

total

668^.597

impact factor

6^.368

average impact factor

SELECTED ARTICLES

Bernstein DI, Lummus ZL, Kesavalu B, Yao J, Kottyan L, Miller D, Cartier A, Cruz MJ, Lemiere C, Munoz X, Quirce S, Tarlo S, Sastre J, Boulet LP, Weirauch MT, Kaufman K.
Genetic Variants with Gene Regulatory Effects are Associated with Diisocyanate Asthma.
J Allergy Clin Immunol. 2018 Sep;142(3):959-969.
doi: 10.1016/j.jaci.2018.06.022.
IF: 13.258
Polverino E, Dimakou K, Hurst J, Angel Martinez-Garci, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD.
The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions.
Eur Respir J. 2018 Sep 15;52(3).
doi: 10.1183/13993003.00328-2018.
IF: 12.242.
Ramon MA, Ter Riet G, Carsin AE, Gimeno-Santos E, Agusti A, Anto JM, Donaire-Gonzalez D, Ferrer J, Rodriguez E, Rodriguez-Roisin R, Puhan MA, Garcia-Aymerich J.
The dyspnoea-inactivity vicious circle in COPD: Development and external validation of a conceptual model.
Eur Respir J. 2018 Sep 15;52(3).
doi: 10.1183/13993003.00079-2018.
IF: 12.242.
Munoz G, de Gracia J, Buxo M, Alvarez A, Vendrell M de Pablos A, Jaramillo M, Ezzahouri I, Garcia S, Navarro J, Lopez-Hoyos M, Carbone J.
Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial.
Eur Respir J. 2018 Jan 11;51(1).
doi: 10.1183/13993003.01926-2017.
IF: 12.242
Greer M, Berastegui C, Jaksch P, Benden C, Aubert J, Roux A, Lhuillier E, Hirschi S, Reynaud-Gaubert M, Philit F, Claustre J, LePalud P, Stern M, Knoop C, Vos R, Verschuuren E, Fisher A, Riise G, Hansson L, Iversen M, Hammainen P, Wedel H, Smits J, Gottlieb J, Holm AM.
Lung transplantation after allogeneic stem cell transplantation: a pan-European experience.
Eur Respir J. 2018 Feb 14;51(2).
doi: 10.1183/13993003.01330-2017.
IF: 12.242

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leaders: Mª Jesús Cruz Carmona and Jaume Ferrer Sancho

Research Areas